ERBB2 and breast cancer: The prognostic value of pCR after NACT depends on the molecular subtype of breast cancer49; TNBC and HER2-enriched patients have higher pCR rates than luminal breast cancer.50 Thirty-three (29.2%) patients achieved pCR, 9 (7.9%) had luminal breast cancer, 21 (18.6%) had HER2 overexpression tumors, and 3 (2.7%) had TNBC.51,52